Treatment outcomes for ARUBA-eligible brain arteriovenous malformations: a comparison of real-world data from the NVQI-QOD AVM registry with the ARUBA trial.
Publication/Presentation Date
12-26-2024
Abstract
BACKGROUND: Significant controversy exists about the management of unruptured cerebral arteriovenous malformations (AVMs). Results from A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA) suggested that intervention increases the risk of stroke/death compared with medical management. However, numerous study limitations raised concerns about the trial's generalizability.
OBJECTIVE: To assess the rate of stroke/death and functional outcomes in ARUBA-eligible patients from a multicenter database, the Neurovascular Quality Initiative-Quality Outcomes Database (NVQI-QOD).
METHODS: We performed a retrospective analysis of prospectively collected data of ARUBA-eligible patients who underwent intervention at 18 participating centers. The primary endpoint was stroke/death from any cause. Secondary endpoints included neurologic, systemic, radiographic, and functional outcomes.
RESULTS: 173 ARUBA-eligible patients underwent intervention with median follow-up of 269 (25-722.5) days. Seventy-five patients received microsurgery±embolization, 37 received radiosurgery, and 61 received embolization. Baseline demographics, risk factors, and general AVM characteristics were similar between groups. A total of 15 (8.7%) patients experienced stroke/death with no significant difference in primary outcome between treatment modalities. Microsurgery±embolization was more likely to achieve AVM obliteration (P< 0.001). Kaplan-Meier survival curves demonstrated no difference in overall death/stroke outcomes between the different treatment modalities' 5-year period (P=0.087). Additionally, when compared with the ARUBA interventional arm, our patients were significantly less likely to experience death/stroke (8.7% vs 30.7%; P< 0.001) and functional impairment (mRS score ≥2 25.4% vs 46.2%; P< 0.01).
CONCLUSION: Our results suggest that intervention for unruptured brain AVMs at comprehensive stroke centers across the United States is safe.
Volume
17
Issue
e1
First Page
1
Last Page
1
ISSN
1759-8486
Published In/Presented At
Alrohimi, A., Achey, R. L., Thompson, N., Abdalla, R. N., Patterson, T., Moazeni, Y., Rasmussen, P. A., Toth, G., Bain, M. D., Ansari, S. A., Hussain, S. M., Moore, N. Z., & NVQI-QOD Registry Investigators (2024). Treatment outcomes for ARUBA-eligible brain arteriovenous malformations: a comparison of real-world data from the NVQI-QOD AVM registry with the ARUBA trial. Journal of neurointerventional surgery, 17(e1), e1–e8. https://doi.org/10.1136/jnis-2023-020525
Disciplines
Medicine and Health Sciences | Physical Sciences and Mathematics
PubMedID
38195249
Department(s)
Department of Surgery Faculty
Document Type
Article